Nautilus Biotechnology, Inc.
NAUTNASDAQHealthcare● Active
$2.33
$-0.06(-2.51%)
Market Cap$296093732
P/E Ratio—
52W High$4.31
52W Low$0.62
Nautilus Biotechnology, Inc. (NAUT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NAUT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
-$0.12
Est. -$0.14 · +17.2%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▲ Beat EPS🔥 11-Quarter EPS Beat Streak
NAUT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.14 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | Apr 28, 2026 | -$0.14 | -$0.12 | +17.2% | — | $0.00B | — |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.14 | -$0.11 | +21.4% | — | $0.00B | — |
| ▲ Q4 FY2025 | Oct 27, 2025 | -$0.15 | -$0.11 | +26.7% | — | — | — |
| ▲ Q3 FY2025 | Jul 31, 2025 | -$0.15 | -$0.12 | +22.6% | — | — | — |
| ▲ Q2 FY2025 | Apr 29, 2025 | -$0.14 | -$0.13 | +7.1% | — | — | — |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$0.16 | -$0.14 | +12.5% | $0.01B | — | — |
| ▲ Q4 FY2024 | Oct 29, 2024 | -$0.17 | -$0.13 | +23.5% | — | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.14
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Beat
EPS Actual
-$0.12
EPS Est.
-$0.14
EPS Surpr.
+17.2%
Revenue
—
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.11
EPS Est.
-$0.14
EPS Surpr.
+21.4%
Revenue
—
Q4 FY2025
Oct 27, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.15
EPS Surpr.
+26.7%
Revenue
—
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.15
EPS Surpr.
+22.6%
Revenue
—
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.14
EPS Surpr.
+7.1%
Revenue
—
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.16
EPS Surpr.
+12.5%
Revenue
$0.01B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
-$0.13
EPS Est.
-$0.17
EPS Surpr.
+23.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q3 FY2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q2 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q1 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q4 FY2026 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q3 FY2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 28, 2026 | +17.2% | $2.57 | $2.59 | +0.78% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +21.4% | $2.89 | $2.42 | -16.26% |
| ▲ Q4 FY2025 | Oct 27, 2025 | +26.7% | $1.22 | $1.35 | +10.66% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +22.6% | $0.76 | $0.76 | +0.00% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +7.1% | $0.68 | $0.73 | +7.97% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +12.5% | $1.47 | $1.43 | -2.72% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +23.5% | $2.81 | $2.77 | -1.42% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +12.5% | $2.74 | $2.67 | -2.55% |
Q2 FY2026+0.78%
Report Date
Apr 28, 2026
EPS Beat/Miss
+17.2%
Price Before
$2.57
Price After
$2.59
Q1 FY2026-16.26%
Report Date
Feb 26, 2026
EPS Beat/Miss
+21.4%
Price Before
$2.89
Price After
$2.42
Q4 FY2025+10.66%
Report Date
Oct 27, 2025
EPS Beat/Miss
+26.7%
Price Before
$1.22
Price After
$1.35
Q3 FY2025+0.00%
Report Date
Jul 31, 2025
EPS Beat/Miss
+22.6%
Price Before
$0.76
Price After
$0.76
Q2 FY2025+7.97%
Report Date
Apr 29, 2025
EPS Beat/Miss
+7.1%
Price Before
$0.68
Price After
$0.73
Q1 FY2025-2.72%
Report Date
Feb 26, 2025
EPS Beat/Miss
+12.5%
Price Before
$1.47
Price After
$1.43
Q4 FY2024-1.42%
Report Date
Oct 29, 2024
EPS Beat/Miss
+23.5%
Price Before
$2.81
Price After
$2.77
Q3 FY2024-2.55%
Report Date
Jul 30, 2024
EPS Beat/Miss
+12.5%
Price Before
$2.74
Price After
$2.67
Avg Beat Reaction-0.44%
Beat Rate8 / 8 quarters
Largest Move-16.26% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NAUT ends December
Nautilus Biotechnology, Inc. (NAUT) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $-0.12 — beating the analyst consensus of $-0.14 by +17.2%. NAUT has beaten EPS estimates for 11 consecutive quarters. The next NAUT earnings date is expected around September 1, 2026.
Each quarter, investors track NAUT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NAUT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NAUT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NAUT earnings · 5 questionsNautilus Biotechnology, Inc.'s next earnings report is expected around September 1, 2026. NAUT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NAUT historically reports after market close (AMC).
NAUT earnings datewhen is NAUT earningsNAUT next earnings datewhen does NAUT report earningsNAUT earnings calendar
▸ Source: FMP · Nautilus Biotechnology, Inc. SEC filings · US GAAP · Nautilus Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026